ImmunityBio shares rose nearly 7% as founder Patrick Soon-Shiong criticized competitors' chemotherapy strategies ahead of Tuesday's earnings. He touted Anktiva's IL-15 mechanism as superior to older treatments. The company is set to report Q4 revenue of $38.3 million, a 431% increase, with 2025 net product revenue surging 700% to $113 million.